{"id":493512,"date":"2024-06-06T09:03:18","date_gmt":"2024-06-06T09:03:18","guid":{"rendered":"https:\/\/www.olympiajournal.com\/news\/story\/493512\/hemophilia-b-market-is-expected-to-showcase-a-significant-growth-during-the-forecast-period-uniqure-biopharma-csl-behring-pfizer-spark-therapeutics-genzyme-novo-nordisk-pfizer-alnylam-pharma.html"},"modified":"2024-06-06T09:03:18","modified_gmt":"2024-06-06T09:03:18","slug":"hemophilia-b-market-is-expected-to-showcase-a-significant-growth-during-the-forecast-period-uniqure-biopharma-csl-behring-pfizer-spark-therapeutics-genzyme-novo-nordisk-pfizer-alnylam-pharma","status":"publish","type":"post","link":"https:\/\/www.oklahomanews-online.com\/news\/story\/493512\/hemophilia-b-market-is-expected-to-showcase-a-significant-growth-during-the-forecast-period-uniqure-biopharma-csl-behring-pfizer-spark-therapeutics-genzyme-novo-nordisk-pfizer-alnylam-pharma.html","title":{"rendered":"Hemophilia B Market Is Expected to Showcase a Significant Growth During the Forecast Period | UniQure Biopharma, CSL Behring, Pfizer, Spark Therapeutics, Genzyme, Novo Nordisk, Pfizer, Alnylam Pharma"},"content":{"rendered":"
\n
\"Hemophilia<\/a><\/div>\n
\n
Hemophilia B Market<\/div>\n<\/div>\n<\/div>\n
The most common treatment for hemophilia B is replacement therapy. BeneFIX, RIXUBIS, IXINITY, ALPROLIX, IDELVION, and REBINYN are the some available recombinant factor IX products in the US. Apart from these, bypassing agents such as Feiba, Novoseven, and SEVENFACT and human plasma-derived coagulation factor IX \u2013 AlphaNine SD and Mononine have bagged the FDA approval as well.<\/div>\n

As per DelveInsight, the Hemophilia B therapeutics market is anticipated to grow in the coming year owing to the rise in the number of cases of Hemophilia B and the launch of the most anticipated gene therapies in the market by major pharma and biotech giants and the rise in the healthcare spending across the world.Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with Hemophilia B. Currently, gene therapies are gaining popularity due to their potential to cure this disease and also the anticipated one-time infusion. Apart from this, increased focus on prophylactic treatment increased usage of extended half-life therapies, and anticipated entry of premium-priced novel hemophilia B treatments will also contribute to the market’s growth.<\/p>\n

DelveInsight’s “Hemophilia B Market Insights, Epidemiology, and Market Forecast 2032<\/strong><\/a>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia B market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Hemophilia B market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.<\/p>\n

Hemophilia B Overview<\/strong><\/p>\n

Hemophilia is defined as an inherited bleeding disorder in which the blood does not clot properly. This can lead to spontaneous bleeding and bleeding following injuries or surgery. It is caused by a gene defect that decides how factors VIII, IX, or XI are produced by the body. One of the Hemophilia types is Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, which is a genetic disorder caused by missing or defective factor IX, a clotting protein.<\/p>\n

Although it is passed down from parents to children, about one-third of cases are caused by a spontaneous mutation, a change in a gene. Clotting factors are specialized proteins needed for blood clotting, the process by which blood seals a wound to stop bleeding and promote healing.<\/p>\n

The two main symptoms are bleeding for longer than normal and bruising easily. Even a small bump on the head can be serious with this disease. Hemophilia B can range from mild to moderate to severe. Individuals with mild hemophilia have factor IX levels between 5 and 40% of normal; those with moderate hemophilia have factor levels from 1 to 5% of normal; and individuals with severe hemophilia have factor levels <1% of normal.<\/p>\n

Hemophilia B Market<\/strong><\/a><\/p>\n

The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Hemophilia B market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.<\/p>\n

The report gives complete detail of the Hemophilia B market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.<\/p>\n

Hemophilia B Epidemiology Assessment<\/strong><\/p>\n

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.<\/p>\n

The Report Covers the Hemophilia B Epidemiology, Segmented as –<\/strong><\/p>\n

Total Diagnosed Prevalent Pool of Hemophilia B<\/p>\n

Treated Prevalent Pool of Hemophilia B<\/p>\n

Severity-specific Prevalent Pool of Hemophilia B<\/p>\n

Prevalent population of Hemophilia B with or without Inhibitors<\/p>\n

Hemophilia B Drugs Uptake and Pipeline Development Activities<\/strong><\/p>\n

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Hemophilia B market or expected to be launched during the study period. The analysis covers the Hemophilia B market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.<\/p>\n

The report also covers the Hemophilia B pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.<\/p>\n

Learn How the Hemophilia B Market Will Evolve and Grow by 2034 @ https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market<\/a><\/p>\n

Leading Companies in the Hemophilia B Therapeutics Market Include:<\/strong><\/p>\n

Alnylam Pharmaceuticals<\/p>\n

ApcinteX Ltd<\/p>\n

Bioverativ Therapeutics<\/p>\n

CSL Behring<\/p>\n

Freeline Therapeutics<\/p>\n

Genzyme, a Sanofi Company<\/p>\n

HEMA Biologics<\/p>\n

LFB Pharmaceuticals<\/p>\n

Novo Nordisk<\/p>\n

Pfizer<\/p>\n

Sangamo Therapeutics<\/p>\n

Sobi<\/p>\n

Spark Therapeutics<\/p>\n

UniQure Biopharma B.V.<\/p>\n

And Many Others<\/p>\n

Hemophilia B Marketed and Emerging Therapies Covered in the Report Include:<\/strong><\/p>\n

Alprolix: Bioverativ Therapeutics\/Sobi<\/p>\n

Concizumab (NN7415): Novo Nordisk<\/p>\n

Concizumab: Novo Nordisk<\/p>\n

Etranacogene dezaparvovec (AMT-061): UniQure Biopharma B.V.\/ CSL Behring<\/p>\n

Fidanacogene elaparvovec (SPK-9001\/PF-06838435): Pfizer\/Spark Therapeutics<\/p>\n

Fitusiran: Genzyme, a Sanofi Company\/ Alnylam Pharmaceuticals<\/p>\n

FLT180a: Freeline Therapeutics<\/p>\n

Idelvion: CSL Behring<\/p>\n

Marstacimab (PF-06741086): Pfizer<\/p>\n

Rebinyn (Nonacog beta pegol): Novo Nordisk<\/p>\n

SB-FIX: Sangamo Therapeutics<\/p>\n

SerpinPC: ApcinteX Ltd<\/p>\n

Sevenfact (coagulation factor VIIa [recombinant]-jncw): HEMA Biologics\/LFB Pharmaceuticals<\/p>\n

Verbrinacogene setparvovec (FLT-180a): Freeline Therapeutics<\/p>\n

And Many More<\/p>\n

The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @ https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market<\/a><\/strong><\/p>\n

Table of Contents<\/strong><\/p>\n

1. Key Insights<\/p>\n

2. Executive Summary<\/p>\n

3. Hemophilia B Competitive Intelligence Analysis<\/p>\n

4. Hemophilia B Market Overview at a Glance<\/p>\n

5. Hemophilia B Disease Background and Overview<\/p>\n

6. Hemophilia B Patient Journey<\/p>\n

7. Hemophilia B Epidemiology and Patient Population (In the US, EU5, and Japan)<\/p>\n

8. Hemophilia B Treatment Algorithm, Current Treatment, and Medical Practices<\/p>\n

9. Hemophilia B Unmet Needs<\/p>\n

10. Key Endpoints of Hemophilia B Treatment<\/p>\n

11. Hemophilia B Marketed Products<\/p>\n

12. Hemophilia B Emerging Drugs and Latest Therapeutic Advances<\/p>\n

13. Hemophilia B Seven Major Market Analysis<\/p>\n

14. Attribute Analysis<\/p>\n

15. Hemophilia B Market Outlook (In US, EU5, and Japan)<\/p>\n

16. Hemophilia B Access and Reimbursement Overview<\/p>\n

17. KOL Views on the Hemophilia B Market<\/p>\n

18. Hemophilia B Market Drivers<\/p>\n

19. Hemophilia B Market Barriers<\/p>\n

20. Appendix<\/p>\n

21. DelveInsight Capabilities<\/p>\n

22. Disclaimer<\/p>\n

Download the Sample PDF to Learn More About the Key Offerings of the Report @ https:\/\/www.delveinsight.com\/sample-request\/hemophilia-b-market<\/a><\/strong><\/p>\n

Media Contact<\/span>
Company Name:<\/strong> DelveInsight Business Research LLP<\/a>
Contact Person:<\/strong> Kritika Rehani
Email:<\/strong> Send Email<\/a>
Phone:<\/strong> +14699457679
Address:<\/strong>304 S. Jones Blvd #2432
City:<\/strong> Las Vegas
State:<\/strong> Nevada
Country:<\/strong> United States
Website:<\/strong> https:\/\/www.delveinsight.com\/<\/a><\/p>\n

<\/object>\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Hemophilia B Market The most common treatment for hemophilia B is replacement therapy. BeneFIX, RIXUBIS, IXINITY, ALPROLIX, IDELVION, and REBINYN are the some available recombinant factor IX products in the<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"_links":{"self":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493512"}],"collection":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/comments?post=493512"}],"version-history":[{"count":0,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/posts\/493512\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/media?parent=493512"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/categories?post=493512"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.oklahomanews-online.com\/news\/wp-json\/wp\/v2\/tags?post=493512"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}